Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Sareum Holdings PLC on Wednesday reported an increased half-year loss for the six months to December 31, as it continued to work on its psorasis candidate drug SDC-1801.
The Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer said interim pretax loss widened 70% to £1.7 million from £1.0 million a year prior, while it does not yet generate revenue.
The company reiterated that it submitted an application to conduct a phase 1 clinical trial on its psoriasis drug SDC-1801 in Australia, which it hopes to begin dosing as soon as possible this year. SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases, with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Sareum Holdings shares fell 3.3% to 87.00 pence each on Wednesday morning in London.
Copyright 2023 Alliance News Ltd. All Rights Reserved.